News

Neurogenic orthostatic hypotension (nOH), a sudden drop in blood pressure when changing positions, can significantly affect Parkinson’s disease patients’ function and quality of life. A recent survey highlights the need for improved awareness and education on the effects and burden of this condition, which affects one in every five Parkinson’s…

Biogen has presented data of its research programs evaluating potential treatments for Parkinson’s disease and progressive supranuclear palsy, an atypical parkinsonian disorder (APD). The data were presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), held Oct. 5-9, in Hong Kong, China. Parkinson’s disease…

A form of vitamin B3 can promote degeneration of nerve cells linked to Parkinson’s disease and exacerbate disease manifestations in mice, a study reveals. Despite the benefits of the compound demonstrated in previous studies, these new contrasting findings suggest that its mechanism of action is complex and not specific for…

Parkinson’s Institute and Clinical Center and Retrotope have paired up to explore the therapeutic potential of the investigational agent RT001 in patients with progressive supranuclear palsy (PSP), a type of treatment-resistant Parkinson’s disease. Under Retrotope’s expanded access program for RT001, the institute’s physicians started dosing two…

The Linked Clinical Trials (LCT) Initiative, a repurposing program that aims to identify existing medicines which can slow the progression of Parkinson’s disease, has resulted in a growing number of clinical trials. The partnership’s history, purpose and activities are the focus of an article, “The Linked Clinical…

The time between diagnosis and implementation of symptomatic treatment is critical in the effort to find a cure for Parkinson’s disease. However, many early Parkinson’s patients wait too long before seeking medical attention, leaving researchers with a small group of candidates for clinical trials, says Robert A. Hauser,…

If the FDA approves Sunovion’s APL-130277 come January, Parkinson’s patients will have a first oral treatment — and a first new treatment in more than a decade — for off episodes, those times of difficulties with movement despite taking treatments that stimulate dopamine receptors, like levodopa. “We think that…

People with inflammatory bowel disease (IBD), an umbrella name for disorders marked by prolonged inflammation of the digestive tract, are at a higher-than-usual risk for Parkinson’s disease, a review study involving 8.9 million IBD patients suggests. The study, “The risk of Parkinson’s disease in inflammatory bowel disease: A…

In 2017, the United Kingdom’s National Institute for Health and Care Excellence (NICE) published its latest guidelines on how adult patients and their caregivers should manage Parkinson’s disease (PD). In a new commentary, four experts discuss the implications of some of these recommendations for both patients and healthcare professionals,…

The new law calling for the federal government to collect data on U.S. residents with neurological conditions such as Parkinson’s will help refine disease research and make care more accessible, the Michael J. Fox Foundation (MJFF) for Parkinson’s Research said. President Donal Trump recently signed into law the Labor,…